A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents

Cancer Research

Volumn 56, Issue 19, 1996, Pages 4328-4331

  Biegon, Anat ^a   Brewster, Marcus ^b   Degani, Hadassa ^c   Pop, Emil ^b   Somjen, Dalia ^d   Kaye, Alvin M ^c  

^a PHARMOS LTD   (Israel)

^b Pharmos Corporation   (United States)

^c Weizmann Infinite of Science ^*  (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN DERIVATIVE; TAMOXIFEN METHIODIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; DOSE RESPONSE; FEMALE; HUMAN TISSUE; MALE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; TISSUE SPECIFICITY; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN CHEMISTRY; BREAST NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN; TISSUE DISTRIBUTION; UTERUS;

EID: 0029758023     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Harper, M J, and Walpole, A. L A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod. Fertil, 13: 101-119, 1967
2. Lerner, L J, and Jordan, V, C Development of antiestrogens and their use in breast cancer Cancer Res, 50 4177-4189, 1990.
3. Jordan, V C. A current view of tamoxifen for the treatment and prevention of breast cancer. Br. J. Pharmacol., 110 507-517, 1993
4. Love, R. R, Wtebe, D. A. Newcomb, P A, Cameron, L., Leventhal, H, Jordan, V. C., Feyzi., J., and DeMets, D. L. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern. Med, 115: 860-864, 1991
5. Love, R. R, Mazess, R. B, Barden, H. S. Epstein, S. Newcomb, P. A, Jordan, V C., Carbone, P. P, and DeMets, D. L Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Eng. J Med., 326, 852-856, 1992.
6. Wiseman, H Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci, 15: 83-89, 1994.
7. Henderson, B E, Ross, R. K., and Pike, M. C. Hormonal chemoprevention of cancer in women Science (Washington DC), 259: 633-638, 1993.
8. Woolley, C. S., and McEwen, B. S. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat J Comp. Neurol., 336: 293-306, 1993.
9. Phillips, S. M., and Sherwin, B. B. Effects of estrogen on memory function in surgically menopausal women Psychoneuroendocrinology, 17: 485-495, 1992.
10. Paganini-Hill, A, and Henderson, V. W. Estrogen deficiency and risk of Alzheimer's disease in women Am. J. Epidemiol., 140: 256-261, 1994.
11. Gottardis, M M., Robinson, S. P, Saryaswaroop, P G, Pondichery, G. S., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse Cancer Res, 48: 812-815, 1988.
12. Jarman, M., Leung, O. T., Leclerq, G, Devleeschouwer, N., Stoessel, S, Coombes, R C., and Skilton, R. A. Analogues of tamoxifen: the role of the basic side chain. Applications of a whole cell oestrogen-receptor binding assay to N-oxides and quaternary salts. Anticancer Drug Des., 1: 259-268, 1986.
13. Somjen, D., Weisman, Y., Harell, A., Berger, E., and Kaye, A. M Direct and sex-specific stimulation by sex steroids of creatine kinase activity and DNA synthesis in rat bone Proc. Natl. Acad. Sci. USA, 86: 3361-3365, 1989.
14. Furman-Haran, E., Maretzel, A. F., Goldberg, I. Horrowitz, A, and Degani, H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth Cancer Res., 54: 5511-5514, 1994
15. Gottardis, M M., Robinson, S. P., and Jordan, V. C. Estradiol-stimulated growth of MCF7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid Biochem., 30: 311-314, 1988
16. Gagliardi, A, and Collins D. C Inhibition of angiogenesis by antiestrogens. Cancer Res., 53: 533-535, 1993.
17. Baltuch, G., Shenouda, G., Langleben, A., and Villemure, J. G High-dose tamoxifen in the treatment of recurrent high-grade glioma a report of clinical stabilization and tumor regression. Can. J. Neurol. Sci., 20: 168-170, 1993.
18. Bottega, R., and Epand, R M Inhibition of protein kinase C by cationic amphiphiles. Biochemistry, 31: 9025-9030, 1992.
19. Friedman, Z. Y, Minz, E., and Selinger, Z. Effects of structural modifications of tamoxifen on phospholipase C and phosphoinositide kinase activities. Isr J. Med. Sci., 31, 158, 1995.
20. Black, L. J., Sato, M, Rowley, E. R., Magee, D. E., Bekele, A, Williams, D. C, Cullinan, G. J., Bendeele, R. Kauffmann, R. F., Bensch, W. R., Frolik, C. A., Termine, J. D., and Bryant, H. U. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin Invest., 93: 63-69, 1994